In what is believed to be the first of its kind, the SONAR trial will use non-invasive ultrasound scans to monitor the maturation of arteriovenous fistulae (AVF) in patients.
Up to half of all AVF fail within the first year and researchers want to know why this happens and if it can be prevented.
Transplant surgeon Gavin Pettigrew, who is leading the nationwide study, said: “Chronic kidney disease (CKD) is a major burden on the NHS and affects around 1.8 million people in England alone.
“Of these, a small minority – 57,000 in 2016 – will progress to ‘end-stage kidney disease’, where regular dialysis treatment or kidney transplantation is needed.
“Haemodialysis, where you are hooked up to a machine which flushes the excess fluid and toxins from your blood, is the most common form of dialysis.
“This is performed either through a major vein or through an AVF, which is created by joining a small artery to a vein, usually in the patient’s arm.
“This is less risky than inserting lines into bigger veins and is more popular among patients.
High failure rate
“The downside is that, despite successful surgery, nearly half of all procedures to create AVF fail in the first year.
“This isn’t harmful to the patient, but we don’t know why this happens or if we can prevent it.”
The SONAR study aims to address both these questions over two stages.
In stage one, researchers will scan 347 patients immediately after their AVF surgery, using non-invasive ultrasound to see if they can spot early problems.
Mr Pettigrew said: “We’ll observe patients for 10 weeks following their surgery, during which they’ll have four ultrasound scans.
“The results from this study will improve our knowledge of how fistulae grow and whether ultrasound can predict problems at an early stage.”
In stage two, more than 1,200 patients will be selected to see if surgical interventions can prevent AVF failure.
Early on Mr Pettigrew invited CKD patient Andrew Norton to join the SONAR steering committee as a lay member.
Andrew said: “My fistula was created two years ago and there were no problems, but I know many people whose fistulae have failed and they’ve had to have the operation again.
“SONAR could shed some light on why this happens, which is why I want to promote the potential benefits of taking part to new patients.”
As the patient representative, Andrew backed the group’s decision to apply to the Addenbrooke’s Kidney Patient Association (AKPA) for funding to cover travel costs for SONAR participants.
He said: “SONAR means an extra four visits for patients and for some this could be too expensive, even if they wanted to take part.
“Now that there is funding for this, it may encourage more patients who are about to have a fistula to join SONAR.”
Mr Pettigrew said: “Our end goal is to show that screening is beneficial, by targeting patients whose AVF is not working sooner and reduce the number of fistulae which fail.
“This will save money and time for the NHS and also improve care for the patients who are undergoing this procedure.
“The study will run over the next 15 months and we’re asking all patients with a new AVF, or who are just about to have one, to come forward and take part.”
To find out more about SONAR visit their website: www.sonartrial.org.uk or follow them on Twitter @SONAR_TRIAL
The SONAR trial is funded by a £1.8m grant from the National Institute for Health Research (NIHR) Health Technology Assessment programme (NIHR HTA reference 17/27/11). Funding from the Addenbrooke’s Kidney Patients Association (AKPA) will help fund local patients’ travel expenses.
SONAR is the acronym for Surveillance Of arterioveNous fistulAe using ultRasound study, sponsored by Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge. SONAR is managed by the Clinical Trials Unit at NHS Blood and Transplant.
To find out more about the NIHR Cambridge Biomedical Research Centre visit cambridgebrc.nihr.ac.uk